Free Trial
NASDAQ:DNTH

Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Dianthus Therapeutics logo
$18.27 -0.58 (-3.08%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Key Stats

Today's Range
$17.88
$18.81
50-Day Range
$16.85
$21.85
52-Week Range
$13.37
$32.27
Volume
119,469 shs
Average Volume
264,294 shs
Market Capitalization
$587.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Consensus Rating
Buy

Company Overview

Dianthus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

DNTH MarketRank™: 

Dianthus Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 694th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dianthus Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Dianthus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dianthus Therapeutics is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dianthus Therapeutics is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dianthus Therapeutics has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dianthus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    29.97% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently increased by 4.39%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Dianthus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dianthus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    29.97% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently increased by 4.39%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Dianthus Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Dianthus Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for DNTH on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dianthus Therapeutics' insider trading history.
Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNTH Stock News Headlines

Analysts Set Expectations for DNTH FY2025 Earnings
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

DNTH Stock Analysis - Frequently Asked Questions

Dianthus Therapeutics' stock was trading at $21.80 at the start of the year. Since then, DNTH stock has decreased by 15.0% and is now trading at $18.53.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 29.26% and a negative net margin of 1,544.23%.

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/12/2025
Today
7/07/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DNTH
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.00
High Stock Price Target
$84.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+186.0%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$84.97 million
Net Margins
-1,544.23%
Pretax Margin
-1,544.26%

Debt

Sales & Book Value

Annual Sales
$6.24 million
Price / Cash Flow
N/A
Book Value
$11.91 per share
Price / Book
1.56

Miscellaneous

Free Float
26,834,000
Market Cap
$595.92 million
Optionable
Optionable
Beta
1.38
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:DNTH) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners